IRMD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
20.5M
-6.9%
22.0M
-3.1%
22.7M
+7.0%
21.2M
+3.9%
20.4M
Cost of Revenue
5.3M
+2.7%
5.2M
-8.7%
5.7M
+20.2%
4.7M
+5.7%
4.5M
Gross Profit
15.2M
-9.8%
16.8M
-1.3%
17.0M
+3.3%
16.5M
+3.4%
16.0M
Operating Expenses
8.8M
-8.4%
9.6M
-3.6%
9.9M
+2.9%
9.7M
+5.4%
9.2M
R&D
657.0K
-31.3%
956.0K
+19.6%
799.0K
+18.5%
674.4K
-23.1%
877.0K
SG&A
8.1M
-5.9%
8.6M
-5.7%
9.1M
+1.7%
9.0M
+8.4%
8.3M
Operating Income
6.4M
-11.7%
7.2M
+2.0%
7.1M
+3.8%
6.8M
+0.7%
6.8M
EBITDA
6.8M
-11.6%
7.7M
+2.9%
7.5M
+3.6%
7.2M
+3.1%
7.0M
Net Income
5.2M
-10.3%
5.8M
-9.7%
6.4M
+15.5%
5.6M
-3.4%
5.8M
EPS (Basic)
$0.41
-10.9%
$0.46
-9.8%
$0.51
+15.9%
$0.44
-2.2%
$0.45
EPS (Diluted)
$0.41
-8.9%
$0.45
-10.0%
$0.50
+16.3%
$0.43
-4.4%
$0.45
Shares (Diluted)
12.9M
+0.0%
12.9M
-0.2%
12.9M
+0.3%
12.9M
+0.2%
12.8M
iRadimed (IRMD) โ€” Financials